Zimmerman, Brandon https://orcid.org/0009-0005-3163-8685
Dakin, Leslie A.
Fortier, Anne
Nanou, Evanthia
Blasio, Angelo
Mann, James
Miller, Howard
Fletcher, Marissa https://orcid.org/0000-0003-1777-8751
Wang, Tiansheng https://orcid.org/0000-0001-5073-2670
Nanthakumar, Suganthini
McCarthy, Gizelle
Matar, Caline
Matsye, Prachi
Wang, Guanyu https://orcid.org/0009-0000-7698-8201
Snyder, Phillip
Daniel, Kevin
Swamy, Harsha https://orcid.org/0000-0002-3840-0195
Sullivan, Kelly
Bright, Franklin
Powers, Audrey
Gagnon, Kevin J.
Lu, Fan
Paula, Steven
Khare-Pandit, Suvarna
Henry, Larry
Hamel, Martine
Denis, Francois
Nicolas, Olivier
Hariparsad, Niresh https://orcid.org/0000-0002-6290-5329
Kumar, Shyamesh
Proctor, Jennifer
Senter, Timothy https://orcid.org/0000-0003-2766-8353
Furey, Brinley
Bunnage, Mark E. https://orcid.org/0009-0002-6063-8041
Article History
Received: 13 February 2024
Accepted: 11 December 2024
First Online: 2 January 2025
Competing interests
: The authors declare the following competing financial interest(s): All authors listed are current or past employees of Vertex Pharmaceuticals, Incorporated and may hold stock in the company. Compound 2, Compound 3 and VX-147 are disclosed and claimed in granted U.S. Patent No. 11,618,746 B2, among other places, where Vertex Pharmaceuticals Incorporated is the applicant. The inventors on the patent are as follows: Jingrong Cao, Jon H. Come, Leslie A. Dakin, Francois Denis, Warren A. Dorsch, Anne Fortier, Martine Hamel, Elaine B. Krueger, Brian Ledford, Suganthini S. Nanthakumar, Olivier Nicolas, Camil Sayegh, Timothy J. Senter, Tiansheng Wang, Michael Brodney, Kan-Nian Hu, Peter Rose, Kevin Gagnon, Yi Shi, Muna Shrestha, Ales Medek, Faith Witkos. The aspects covered in the manuscript that are found in the patent application are Compound 2, Compound 3 and VX-147, in addition to the thallium flux and trypanosome rescue assay and their use in discovering these inhibitors.